New hope for kids with rare swelling disorder
NCT ID NCT07216378
Summary
This program provides early access to an experimental drug called sebetralstat for children aged 2-11 with hereditary angioedema (HAE). The goal is to treat sudden, painful swelling attacks as they happen. Doctors will give the medication to eligible children to see if it can quickly control these dangerous episodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KalVista Investigative Site
AVAILABLEEvansville, Indiana, 47715, United States
-
KalVista Investigative Site
AVAILABLEWheaton, Maryland, 20902, United States
-
KalVista Investigative Site
AVAILABLESt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.